Glycemic Control and Cardiovascular Disease in 7,454 Patients With Type 1 Diabetes: An observational study from the Swedish National Diabetes Register (NDR) by Eeg-Olofsson, Katarina et al.
Glycemic Control and Cardiovascular
Disease in 7,454 Patients With Type 1
Diabetes
An observational study from the Swedish National Diabetes
Register (NDR)
KATARINA EEG-OLOFSSON, MD
1
JAN CEDERHOLM, MD, PHD
2
PETER M. NILSSON, MD, PHD
3
BJ¨ ORN ZETHELIUS, MD, PHD
4
ANN-MARIE SVENSSON, RN, PHD
5
SOFFIA GUDBJ¨ ORNSD´ OTTIR, MD, PHD
1
BJ¨ ORN ELIASSON, MD, PHD
1
OBJECTIVE — We assessed the association between A1C and cardiovascular diseases
(CVDs) in an observational study of patients with type 1 diabetes followed for 5 years.
RESEARCH DESIGN AND METHODS — A total of 7,454 patients were studied from
the Swedish National Diabetes Register (aged 20–65 years, diabetes duration 1–35 years, fol-
lowed from 2002 to 2007).
RESULTS — Hazard ratios (HRs) for fatal/nonfatal coronary heart disease (CHD) per 1% unit
increase in baseline or updated mean A1C at Cox regression analysis were 1.31 and 1.34 and
1.26 and 1.32, respectively, for fatal/nonfatal CVD (all P  0.001 after adjustment for age, sex,
diabetes duration, blood pressure, total and LDL cholesterol, triglycerides, BMI, smoking, and
historyofCVD).HRswereonlyslightlylowerforCHD(P0.002)andCVD(P0.002–0.007)
after also adjusting for albuminuria. Adjusted 5-year event rates of CHD and CVD increased
progressively with higher A1C, ranging from 5 to 12%, as well as when subgrouped by shorter
(1–20 years) or longer (21–35 years) duration of diabetes. A group of 4,186 patients with A1C
5–7.9% (mean 7.2) at baseline showed risk reductions of 41% (95% conﬁdence intervals:
15–60) (P  0.005) for fatal/nonfatal CHD and 37% (12–55) (P  0.008) for CVD, compared
with 3,268 patients with A1C 8–11.9% (mean 9.0), fully adjusted also for albuminuria.
CONCLUSIONS — This observational study of patients in modern everyday clinical prac-
tice demonstrates progressively increasing risks for CHD and CVD with higher A1C, indepen-
dently of traditional risk factors, with no J-shaped risk curves. A baseline mean A1C of 7.2%
showed considerably reduced risks of CHD and CVD compared with A1C 9.0%, emphasizing
A1C as a strong independent risk factor in type 1 diabetes.
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P
atients with type 1 diabetes have
long been considered to have in-
creased risks of cardiovascular dis-
ease (CVD) and mortality (1,2), and this
has recently been conﬁrmed in two stud-
ies (3,4) from the General Practice Re-
searchDatabaseintheU.K.Basedondata
from 1992 to 1999, risks of CVD and
mortality were four to eight times higher
in men and women with type 1 diabetes
than nondiabetic individuals (3,4).
While the association between glyce-
mia and microvascular complications is
established (5,6), there have been no
long-term randomized clinical studies
satisfactorily examining the relationship
withmacrovascularcomplicationsintype
1 diabetes, and epidemiological studies
have shown conﬂicting results (7–14).
The Epidemiology of Diabetes Interven-
tions and Complications (EDIC) Study
showed that patients who had previously
been subjected to intensive glucose con-
trol during the Diabetes Control and
Complications Trial (DCCT) had a con-
siderably lower risk of CVD than patients
receiving standard treatment (1983–
1993) (7). A small study from Finland on
late-onsettype1diabeticpatientswithout
albuminuria showed increased risk of
coronary heart disease (CHD) with poor
glycemic control (9), but the EURODIAB
Prospective Complications Study (PCS),
the Pittsburgh Epidemiology of Diabetes
Complications (EDC) Study, and the
Wisconsin Epidemiologic Study of Dia-
betic Retinopathy did not demonstrate a
signiﬁcant relationship between glycemia
and CHD after controlling for other car-
diovascular risk factors (10–13). How-
ever, a recent study (14) from the
Pittsburgh EDC showed that change in
A1C was related to coronary artery dis-
ease, whereas baseline A1C was not.
With this background, we assessed
the association between A1C and CHD,
stroke, and CVD in a large cohort of pa-
tients with type 1 diabetes, aged 20–65
years,treatedineverydayclinicalpractice
from 2002 to 2007. Data were used from
the Swedish National Diabetes register
(NDR), a quality-assurance tool in diabe-
tes care with nationwide coverage with
recently published reports regarding type
1 and type 2 diabetes (15–17).
RESEARCH DESIGN AND
METHODS— The NDR was initiated
in 1996, and annual reporting is carried
out by trained physicians and nurses via
the Internet or via transfer from clinical
records databases, with information col-
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patient clinics and primary-care clinics
nationwide. All included patients have
agreedbyinformedconsenttoberegistered
beforeinclusion,andallinformationissub-
sequently stored in a central database.
This observational study, approved
by the regional ethics review board at the
University of Gothenburg, consists of
7,454 female and male patients with type
1 diabetes, with an age range of 20–65
years, diabetes duration of 1–35 years,
and data available in the NDR for all ana-
lyzed variables. Patients with a history of
CVD were not excluded. Baseline clinical
characteristics were estimated in 2002–
2003,andthepatientswerefollowedfora
maximum of 5 years, until 2007. The ep-
idemiologicaldeﬁnitionoftype1diabetes
usedherewastreatmentwithinsulinonly
and onset age of diabetes 30 years. Al-
most all participants in this study (97%)
weretreatedinhospitalclinics.Anassess-
ment of type of diabetes performed vol-
untarily by the reporting clinics, available
in 75% of all participants, showed that
97% had type 1 diabetes.
All participants were divided at base-
line into two groups. One group included
4,186 patients and was deﬁned to have
A1C within the interval 5.0–7.9% at
baseline of the study. The other group of
3,268 patients had A1C within the inter-
val 8.0–11.9%. Both groups were fol-
lowed-up for CVDs during 5 years.
Examinations at baseline
Clinical characteristics evaluated at base-
line were sex, age (years), diabetes dura-
tion (years), A1C (%), weight (kg), height
(m), systolic blood pressure (mmHg), to-
tal cholesterol (mmol/l), LDL cholesterol
(mmol/l), triglycerides (mmol/l), smok-
ing, microalbuminuria (g/min), and
macroalbuminuria (g/min). BMI (kg/m
2)
was calculated as weight in kilograms
divided by the square of height meters.
The Swedish standard for blood pressure
recording,usedintheNDR,wasthemean
value of two supine readings (Korotkoff
1–5)withacuffofappropriatesizeafterat
least 5 min of rest. A smoker was deﬁned
as a patient smoking one or more ciga-
rettesperday,orsmokingtobaccousinga
pipe,orwhohadstoppedsmokingwithin
the past 3 months.
Laboratory analyses of A1C, blood
lipids, and albuminuria values were car-
ried out at local laboratories. A1C analy-
ses are quality assured nationwide by
regular calibration with the high-
performance liquid chromatography
Mono-S method. In this study, all A1C
values were converted to the DCCT stan-
dard values using the following formula:
A1C (DCCT) 0.923 A1C (Mono-S) 
1.345 (R
2  0.998) (18). A1C was mea-
sured at baseline. A1C was also measured
over time as an updated mean of annual
measurements, calculated for each indi-
vidual from baseline to each year of fol-
low-up, with the last observation carried
forward for missing data. In case of an
event during follow-up, the period for es-
timating updated mean A1C was from
baseline to the year before this event oc-
curred. Otherwise, this period was from
baseline to the censor year.
LDL cholesterol values were calcu-
lated using the Friedewald formula (LDL
cholesterol  total cholesterol  HDL
cholesterol  [0.45  triglycerides]), if
triglycerides were 4.0 mmol/l (19). Al-
buminuria was deﬁned as micro- or mac-
roalbuminuria. Microalbuminuria was
deﬁned as urine albumin excretion 20–
200 g/min in two of three consecutive
tests and macroalbuminuria as a urine al-
bumin excretion of 200 g/min.
Follow-up and deﬁnition of end
points
All patients were followed from baseline
until a cardiovascular event or death or
otherwise until censor date 31 December
2007. Mean follow-up was 4.95 years.
Thefollowingendpointswereused:fatal/
nonfatal CHD, fatal/nonfatal stroke,
fatal/nonfatal CVD and total mortality.
Fatal CHD was deﬁned as ICD-10 codes
I20–I25 (available at http://www.who.
int/classiﬁcations/icd/en/). A nonfatal
CHD event was deﬁned as nonfatal myo-
cardial infarction (ICD-10 code I21),
unstable angina (ICD-10 code I20.0),
percutaneouscoronaryintervention,and/
or coronary artery bypass graft. Fatal/
nonfatal stroke was deﬁned as fatal or
nonfatal intracerebral hemorrhage, cere-
bral infarction, or unspeciﬁed stroke
(ICD-10 codes I61, I63, I64, and I67.9).
Fatal/nonfatal CVD was fatal/nonfatal
CHD or stroke, whichever came ﬁrst.
Allendpointeventswereretrievedby
data linkage with the Swedish Cause of
Death and Hospital Discharge Registers
(National Board of Health and Welfare,
Sweden), which is a reliable validated al-
ternative to revised hospital discharge
records and death certiﬁcates (20,21).
Statistical methods
Mean values with 1 SD and SE and fre-
quencies (%) with SE of baseline charac-
teristics,andnumbersandincidencerates
(events per 1,000 person-years) of out-
comes, are given in Table 1. Signiﬁcance
of differences was estimated with Student
t test for mean values, 
2 test for frequen-
cies, and log-rank test at survival analysis
for outcome incidences.
Cox regression analysis was used to
estimate hazard ratios (HRs) with 95%
CIsforA1Casacontinuousvariableorfor
a lower A1C interval versus a higher in-
terval and the outcomes (Table 2) ad-
justed for covariates as given in the table.
The updated mean A1C value was treated
as a strictly time-dependent variable in
the Cox regression analysis to evaluate
glycemic exposure during follow-up, al-
lowing the use of the most recent value of
updated mean A1C at each speciﬁc point
oftimeinthemodelingprocess.Incaseof
an event during follow-up, the period for
estimating updated mean A1C was from
baseline to the year before this event oc-
curred. Otherwise, this period was from
baseline to the censor year. The propor-
tional hazards assumption was conﬁrmed
for all covariates with the Kolmogorov-type
supremum test using resampling and with
the test of all time-dependent covariates si-
multaneously. Maximum likelihood esti-
mation was used to evaluate interaction
betweenA1Candallcovariates,withnosig-
niﬁcant interaction found.
ACoxregressionmodelwasalsoused
to estimate 5-year event rates (1  sur-
vival rate) for CVDs (Fig. 1), in which
model output was the adjusted 5-year
eventrateineachparticipant,adjustedfor
covariates as given in Table 2. Stratiﬁca-
tion (SAS Phreg; Strata) was performed to
achieve adjusted mean event rates by
groupsordecilesoflowerandhigherA1C
(Table 2; Fig. 1). Subgrouping of event
rates by sample intervals has also been
used in the Framingham Study (22). The
signiﬁcance of the difference in mean
event rates between lower and higher
A1C groups was estimated with Student t
test, after logarithmic transformation of
event rates to achieve a normal distribu-
tion. All statistical analyses were per-
formed using SAS version 9.1.3 (SAS
Institute). P  0.05 was considered sta-
tistically signiﬁcant.
RESULTS
Baseline characteristics
Table 1 shows baseline characteristics in
all 7,454 patients. The age range was
20–65 years (mean 37), the range of dia-
betesdurationwas1–35years(mean20),
Eeg-Olofsson and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 7, JULY 2010 1641and mean A1C was 8.0%. Albuminuria
was present in 20% of subjects and a his-
tory of CVD at baseline in 3% of subjects.
Twopatientgroupsarealsoshown:4,186
patients with A1C at baseline of the study
within the interval 5.0–7.9% (mean 7.2)
and 3,268 patients within 8.0–11.9%
(mean 9.0). The group with higher A1C
had somewhat higher mean values of
most risk factors and higher frequencies
of smoking and albuminuria.
Events
In total, 154 CVD events occurred, of
which 36 were fatal and 118 nonfatal
(Table 1). Events per 1,000 person-years
for fatal/nonfatal CHD and CVD in all pa-
tients were 4.0 and 4.7, respectively
(basedon32,931person-years),higherin
the group with higher A1C at baseline
than in those with lower A1C at baseline.
The incidence of total mortality was sim-
ilar in the two A1C groups, and consider-
ably more cases were non-CVD mortality
than fatal CVD.
A1C in all patients
Analyzing baseline A1C as a continuous
variable, Table 2 shows increased HRs
(95% CI) per 1% unit increase in A1C for
fatal/nonfatalCHDandCVD(1.31[1.12–
1.52] and 1.26 [1.09–1.45], P  0.001)
after adjustment for age, sex, diabetes du-
ration, systolic blood pressure, smoking,
total and LDL cholesterol, triglycerides,
BMI, and a history of CVD. These HRs
(95% CI) for CHD and CVD were only
somewhat attenuated after adjusting also
for albuminuria (1.28 [1.09–1.49;], P 
0.002,and1.22[1.06–1.40],P0.007).
HRs for fatal/nonfatal stroke and total
mortality were nonsigniﬁcant.
Using updated mean A1C, similar
strong associations with CHD and CVD
were found. HR for CHD decreased
slightly from 1.34 (95% CI 1.14–1.58;
P  0.001) to 1.30 (1.10–1.53; P 
0.002) when adjusting also for albumin-
uria, and HR for CVD decreased from
1.32 (1.14–1.54; P  0.001) to 1.27
(1.09–1.80; P  0.003). Adjusted 5-year
event rates of CHD and CVD by baseline
A1C or updated mean A1C ranging from
5 to 12% are presented in Fig. 1A and B,
showing progressively increasing event
rateswithhigherA1C.Noelevatedriskwas
seenatthelowestA1Clevels,asalsoveriﬁed
withmeanCHDandCVDratesbydecilesof
updated mean A1C (Fig. 1C and D).
When subgrouped by median dura-
tion, patients with longer duration
(21–35 years [mean 28]) had a higher ad-
justed mean rate of CVD (4.0%) than
Table 1—Baseline clinical characteristics in all 7,454 patients with type 1 diabetes, aged 20–65 years, and outcomes when followed-up for 5
years
All patients
Group at baseline Group at baseline
P value A1C 5.0–7.9% A1C 8.0–11.9%
n 7,454 4,186 3,268
A1C (%) 8.0 (1.2–0.01) 7.2 (0.6–0.01) 9.0 (0.8–0.01) 0.001
Age (years) 36.9 (10.0–0.12) 36.4 (9.8–0.15) 37.4 (10.2–0.18) 0.001
Diabetes duration (years) 19.9 (9.1–0.11) 19.1 (9.3–0.14) 20.9 (8.9–0.15) 0.001
Systolic blood pressure (mmHg) 125.3 (14.9–0.17) 124.2 (14.3–0.22) 126.7 (15.5–0.27) 0.001
Total cholesterol(mmol/l) 4.82 (0.9–0.01) 4.72 (0.9–0.01) 4.95 (0.9–0.02) 0.001
LDL cholesterol (mmol/l) 2.75 (0.8–0.01) 2.67 (0.8–0.01) 2.85 (0.8–0.01) 0.001
Triglycerides (mmol/l) 1.09 (0.6–0.01) 1.0 (0.5–0.01) 1.21 (0.6–0.01) 0.001
BMI (kg/m
2) 25.3 (3.7–0.04) 25.1 (3.5–0.06) 25.5 (3.8–0.07) 0.001
Male sex 55.8 (0.58) 55.9 (0.77) 55.6 (0.87) n.s.
Smoker 13.5 (0.40) 10.0 (0.46) 18.0 (0.67) 0.001
Albuminuria 19.6 (0.46) 14.1 (0.54) 26.7 (0.7) 0.001
Microalbuminuria 12.2 (0.38) 9.3 (0.45) 15.9 (0.64) 0.001
Macroalbuminuria 7.4 (0.30) 4.7 (0.33) 10.8 (0.54) 0.001
History of CVD 2.6 (0.18) 2.0 (0.22) 3.2 (0.31) 0.01
Antihypertensive drugs 24.4 (0.50) 20.2 (0.62) 29.8 (0.8) 0.001
Lipid-lowering drugs 16.6 (0.43) 12.4 (0.51) 21.8 (0.72) 0.001
Acetylsalicylic acid 6.8 (0.29) 5.7 (0.36) 8.0 (0.47) 0.001
Outcomes 	n (events per 1,000 person years)

Fatal CVD 36 17 19
Fatal CHD 34 17 17
Fatal stroke 4 0 4
Non-fatal CVD 118 38 80
Non-fatal CHD 97 28 69
Non-fatal stroke 33 14 19
Fatal/non-fatal CHD 131 (4.0) 45 (2.4) 86 (6.0) 0.001
Fatal/nonfatal stroke 37 (1.1) 14 (0.7) 23 (1.6) 0.05
Fatal/nonfatal CVD 154 (4.7) 55 (3.0) 99 (6.9) 0.001
Total mortality 94 (2.8) 50 (2.7) 44 (3.0) n.s.
Non-CVD mortality 58 33 25
Data for baseline characteristics are means with standard deviation and standard error (SD-SE) or percent frequencies with standard error (SE). Data for outcomes
are numbers, with crude events per 1000 person years in parenthesis. Two groups at baseline are also shown, deﬁned to have an A1C within a lower or a higher
interval at baseline of the study. Albuminuria: microalbuminuria (urine albumin excretion 20–200 g/min) or macroalbuminuria (200 g/min).
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[mean 12]; adjusted mean rate of CVD
0.8%) (see Table 2).
Figure 1E–H shows progressively in-
creasing rates of CHD and CVD with
higher A1C in both subgroups. HRs for
these outcomes per 1% unit increase in
A1C were signiﬁcant in both subgroups.
Groups at baseline by intervals of
A1C
HRs for fatal/nonfatal CHD and CVD,
fully adjusted also for albuminuria, were
1.71 (95% CI 1.18–2.48; P  0.005) and
1.59 (1.13–2.24; P  0.008) for a group
of3,268patientswithhigherA1Catbase-
line (8.0–11.9% [mean 9.0]) compared
with a group of 4,186 patients with A1C
5.0–7.9% (mean 7.2), when followed for
5 years. Correspondingly, the group with
lower A1C showed risk reductions of
41% for CHD and 37% for CVD. These
ﬁndings were consistent when patients
withahistoryofCVDwereexcludedfrom
Cox regression analysis (HRs for CHD
andCVDwithmeanA1C9.0%compared
with mean A1C 7.2% were 1.63 [1.08–
2.45] and 1.72 [1.18–2.52] when unad-
justed for albuminuria and 1.54 [1.02–
2.33] and 1.61 [1.10–2.36] when
adjusted for albuminuria).
Other risk factors at baseline
A comparison between 154 patients who
developed CVD during follow-up and
those 7,300 patients with no CVD
showed that patients with CVD were
older ([means  SD] 48  9 vs. 37  10
years); had longer diabetes duration
(28  7 vs. 20  9 years); had higher
mean systolic blood pressure (136  18
vs. 125  15 mmHg), LDL cholesterol
(3.1  1.1 vs. 2.7  0.8 mmol/l), and
triglycerides (1.4  0.7 vs. 1.1  0.6
mmol/l) (all differences P  0.001); and
had a higher mean BMI (26.1  4.3 vs.
25.3  3.6 kg/m
2, P  0.01). Those with
CVD events had higher frequencies of
smokers (29 vs. 13%), history of CVD be-
fore baseline (20 vs. 2%), and albumin-
uria (49 vs. 19%)—microalbuminuria
(21 vs. 12%) and macroalbuminuria (28
vs. 7%)—all P  0.001.
CONCLUSIONS — This large obser-
vational study of younger and middle-
aged patients (aged 20–65 years) with
type 1 diabetes of varying duration,
treatedineverydayclinicalpractice,dem-
onstrates a strong association between
A1C and both CHD and CVD. Each 1%
unit increase in baseline A1C or updated
mean A1C was associated with risk in-
creases of 31–34% for CHD and 26–32%
for CVD, after adjustment for age, sex,
diabetes duration, and traditional cardio-
vascular risk factors. These increases in
riskremainedsigniﬁcantbutwereslightly
attenuated to 28–30% and 22–27%, re-
spectively, after adjustment also for albu-
minuria. Fully adjusted 5-year event rates
of CHD and CVD increased progressively
with higher A1C levels, and no J-shaped
risk curves were seen. The group with
mean A1C 7.2% at baseline had risk re-
ductions of 41% for CHD and 37% for
CVDcomparedwiththegroupwithmean
9.0%, when followed for 5 years.
Themostpreviouscomparableepide-
miologicalstudieshavenotdemonstrated
clear associations between glycemic con-
Table 2—HRs for CVDs or total mortality and baseline or updated mean A1C in 7,454 patients with type 1 diabetes followed for 5 years
Patients
n/events n/event
rate (%)*
Baseline A1C as predictor Updated mean A1C as predictor
HR (95% CI)† HR (95% CI)‡ HR (95% CI)† HR (95% CI)‡
A1C per 1% unit increase
Fatal/nonfatal CHD
All patients 7,454/131/2.0 1.31 (1.12–1.52)§ 1.28 (1.09–1.49)  1.34 (1.14–1.58)§ 1.30 (1.10–1.53) 
Duration 1–20 years 3,763/25/0.8 1.49 (1.08–2.05)¶ 1.46 (1.06–2.01)¶ 1.45 (1.03–2.03)¶ 1.41 (1.01–1.97)¶
Duration 21–35 years 3,691/106/3.2 1.30 (1.10–1.54)  1.27 (1.07–1.50)  1.38 (1.15–1.67)§ 1.34 (1.11–1.62) 
Fatal/nonfatal stroke
All patients 7,454/37/0.6 1.12 (0.83–1.51) 1.08 (0.80–1.47) 1.24 (0.89–1.72) 1.19 (0.86–1.66)
Fatal/nonfatal CVD
All patients 7,454/154/2.4 1.26 (1.09–1.45)§ 1.22 (1.06–1.40)  1.32 (1.14–1.54)§ 1.27 (1.09–1.80) 
Duration 1–20 years 3,763/26/0.8 1.49 (1.09–2.04)¶ 1.46 (1.07–2.00)¶ 1.48 (1.06–2.07)¶ 1.44 (1.04–2.01)¶
Duration 21–35 years 3,691/128/4.0 1.23 (1.06–1.44)  1.19 (1.02–1.39)¶ 1.34 (1.13–1.59)§ 1.29 (1.08–1.53) 
Total mortality
All patients 7,454/94/1.4 0.97 (0.80–1.17) 0.92 (0.76–1.11) 1.04 (0.85–1.28) 0.98 (0.80–1.20)
A1C intervals (mean) at baseline in
two patient groups
Fatal/non-fatal CHD
5.0–7.9% (7.2) 4,186/45/1.2 1.0 1.0
8.0–11.9% (9.0) 3,268/86/2.9§ 1.80 (1.24–2.60)  1.71 (1.18–2.48) 
Fatal/non-fatal stroke
5.0–7.9% (7.2) 4,186/14/0.5 1.0 1.0
8.0–11.9% (9.0) 3,268/23/0.8§ 1.51 (0.76–2.98) 1.40 (0.70–2.79)
Fatal/non-fatal CVD
5.0–7.9% (7.2) 4,186/55/1.6 1.0 1.0
8.0–11.9% (9.0) 3,268/99/3.3§ 1.70 (1.21–2.38)  1.59 (1.13–2.24) 
HRsforCVDsper1%unitincreaseinA1C,orwithapatientgroupwithA1Catbaseline8–11.9%,comparedwithanothergroupwithA1Catbaseline5–7.9%,when
followed for 5 years. *Mean event rates in a Cox model adjusted as in model 2. †Model 1: adjusted for age, sex, diabetes duration, systolic blood pressure, total
cholesterol, LDL cholesterol, triglycerides, BMI, smoking, and a history of CVD. ‡Model 2: adjusted as in model 1 and also for albuminuria (20 g/min).
Signiﬁcance level for the difference between two mean log event rates and for HRs. §P  0.001;  P  0.01; ¶P  0.05.
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EURODIAB PCS (11) and the Pittsburgh
EDC trials (10,14) were smaller with re-
spect to the numbers of participating pa-
tients, although the follow-up periods
were longer. The mean duration of diabe-
tes was shorter in the EURODIAB PCS,
whiletheyweresimilartoourstudyinthe
Pittsburgh EDC. In our study, two sub-
groups by the median duration are pre-
sented, with 1–20 years and 21–35 years
ofdiabetesduration.Althoughthosewith
longerdiabetesdurationhadhighermean
rates of CHD and CVD, the event rate
curve increased progressively with higher
A1Cinbothsubgroups,veriﬁedbysignif-
icant HRs for these outcomes per unit
A1C increase. Interestingly, there was no
increase in risk at low A1C levels even
with longer duration, a possibility that
has been discussed in generally older pa-
tients with type 2 diabetes (23).
The DCCT/EDIC study provides the
most convincing evidence regarding gly-
cemic control and risk of CVD in type 1
diabetes (7). Patients were randomized to
intensive or standard treatment and fol-
lowedfor6yearsduringtheDCCT.Inthe
subsequent observational EDIC study of
1,182 patients, two groups with mean
Figure 1—Five-year rates (%) of fatal/nonfatal CHD and CVD in a Cox regression model, fully adjusted as in model 2 of Table 2. A and B: Splines
foreventratesinall7,454patients,asacubicfunctionofbaselineA1C(solidline)orupdatedmeanA1C(dashedline).CandD:Adjustedmean(SD)
rates by deciles of updated mean A1C, with a solid line for the linear association by deciles. E–H: Splines for event rates in subgroups by median
duration 20 years.
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mean diabetes duration 12 years, and al-
buminuria 7 vs. 13%) were followed for
another 11 years regarding CVD out-
comes, and, in total, 144 CVD events oc-
curred in 83 patients. Risk reductions of
42% for any ﬁrst-incident CVD and 57%
for fatal/nonfatal CVD with lower A1C
was found at univariate survival analysis
(P  0.02), unadjusted for albuminuria.
We found a risk reduction of 41% for
CVD, unadjusted for albuminuria, in the
group with mean A1C 7.2% compared
with those with mean 9.0% (P  0.002).
Both studies showed similar differ-
ence in baseline mean A1C of 1.7–1.8%
between the groups, similar mean ages,
and generally quite comparable baseline
risk factor levels. Mean duration and fre-
quency of albuminuria were slightly
higher in this study. The confounding ef-
fect of the inclusion of 3% of all patients
with a history of CVD in this study, rea-
sonablyalsopresentinthenormalpatient
population treated in clinical practice,
was adjusted for at the Cox regression
analysis. Our study on data from 2002 to
2007 provides strong support to the re-
sults of the EDIC study conducted from
1994 to 2005. Furthermore, a signiﬁcant
risk reduction for CHD with improved
glycemic control was demonstrated here
but not in the DCCT/EDIC study.
The present study also emphasizes
the role of albuminuria as a risk factor for
CVD in type 1 diabetes. It has been sug-
gested that glycemia is a more potent risk
factor of macrovascular disease in the ab-
senceofalbuminuria(9,14,24,25).Inour
study, the HRs for CHD and CVD were
1.31 and 1.26, respectively, per 1% unit
increase in baseline A1C, when adjusted
for important CVD risk factors except al-
buminuria (P  0.001), and were attenu-
ated to 1.28 and 1.22, respectively, when
adjusted also for albuminuria (P 
0.002–0.007). The HR for CVD with the
groupwithlowerA1Cwas0.59whenun-
adjusted, but it attenuated to 0.63 when
adjusted for albuminuria. In the Cox re-
gression analysis of the DCCT/EDIC
study, the HR for the intensive treatment
group effect on CVD was 0.53 when ad-
justed only for risk factors at DCCT base-
line (P  0.005) but attenuated to 0.58–
0.62 when adjusted also for in-treatment
differences in albuminuria between the
groups during the EDIC study follow-up
(P  0.02–0.04). Thus, both risk factors
are important, and, furthermore, their ef-
fects on risk seem to be additive as we
found no interaction between them.
Although observational studies gen-
erally are regarded as evidence of lower
degree than randomized controlled trials,
such trials often use strict inclusion and
exclusion criteria, which may limit their
application to the normal patient popula-
tion. This study allowed for an analysis of
patients with daily treatment at hospitals
nationwide during recent years with no
exclusioncriteriaregardingriskfactorsor
history of CVD. A major strength of this
study was the large number of patients
and person-years, and it has not as yet
been possible to perform randomized
trials of tight glycemic control in type 1
diabetes with a larger number of partici-
pants included. It is important to adjust
for confounding variables in an observa-
tional study, and such adjustments were
made for age, sex, duration, and several
traditional cardiovascular risk factors, in-
cluding albuminuria representing mi-
croangiopathy, as well as history of CVD.
Analysisofinteractionsarealsoimportant
for reliable results, and we could exclude
heterogeneity as there were no signiﬁcant
interactions between A1C and all in-
cluded covariates. The capture of data on
the outcomes was based on reliable and
validated national registers of morbidity
and mortality.
Therewerealsolimitations.Although
substantial adjustments were made for
confounding variables, unmeasured con-
founding may exist because of unknown
and not included covariates. Data from
participating centers may vary slightly in
accuracy, although increased use of com-
puter software with direct transfer of data
are reducing this problem. Laboratory
analyses are carried out in local laborato-
ries, but there is a nationwide program to
allow calibration of A1C to a standard,
and there have been only very marginal
changes in the cross-sectional mean A1C
values during the study period. There is
also currently no information on auto-
nomic neuropathy, frequency or severity
of hypoglycemia, or detailed informa-
tion on types of insulin used or doses in
the NDR.
In conclusion, this observational
study in a large number of type 1 diabetic
patientsinmoderneverydayclinicalprac-
tice demonstrates a strong independent
effect of increased baseline or updated
mean A1C values on risks of CHD and
CVD, with no sign of a J-shaped curve at
lower A1C values even with longer diabe-
tes duration. A risk reduction of 40%
for CHD and CVD was found when a
group with A1C mean 7.2% at baseline
and followed for 5 years was compared
with a group with baseline A1C mean
9.0%. This emphasizes the role of A1C as
a strong independent risk factor in type 1
diabetes.
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